• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

缺乏指状结构域但具有高纤维蛋白亲和力的组织型纤溶酶原激活剂在大肠杆菌中的表达

Expression in E. coli of finger-domain lacking tissue-type plasminogen activator with high fibrin affinity.

作者信息

Kagitani H, Tagawa M, Hatanaka K, Ikari T, Saito A, Bando H, Okada K, Matsuo O

出版信息

FEBS Lett. 1985 Sep 9;189(1):145-9. doi: 10.1016/0014-5793(85)80860-7.

DOI:10.1016/0014-5793(85)80860-7
PMID:3896853
Abstract

Tissue-type plasminogen activator (t-PA) has a high affinity for fibrin and induces lysis of fibrin (fibrinolysis) on the surface of fibrin without degrading circulating fibrinogen. cDNA for t-PA which lacks the 'finger-domain' (the site for fibrin affinity) was isolated from Detroit 562 cells. Analysis of the nucleotide sequence revealed a lack of the sequences which code for the finger-domain. A plasmid (pDPAT 1) containing the Escherichia coli tac promoter/operator and the cDNA sequence coding for 'finger-domain lacking t-PA' was constructed for expression in E. Coli. The polypeptide so produced was a new type of t-PA lacking finger-domain, but revealed plasminogen activator activity with the function of fibrin affinity.

摘要

组织型纤溶酶原激活剂(t-PA)对纤维蛋白具有高亲和力,并能在纤维蛋白表面诱导纤维蛋白溶解(纤溶作用),而不会降解循环中的纤维蛋白原。从底特律562细胞中分离出了缺乏“指状结构域”(纤维蛋白亲和力位点)的t-PA的cDNA。对核苷酸序列的分析显示,编码指状结构域的序列缺失。构建了一个含有大肠杆菌tac启动子/操纵子以及编码“缺乏指状结构域的t-PA”的cDNA序列的质粒(pDPAT 1),用于在大肠杆菌中表达。如此产生的多肽是一种新型的缺乏指状结构域的t-PA,但具有纤维蛋白亲和力功能的纤溶酶原激活剂活性。

相似文献

1
Expression in E. coli of finger-domain lacking tissue-type plasminogen activator with high fibrin affinity.缺乏指状结构域但具有高纤维蛋白亲和力的组织型纤溶酶原激活剂在大肠杆菌中的表达
FEBS Lett. 1985 Sep 9;189(1):145-9. doi: 10.1016/0014-5793(85)80860-7.
2
Construction and expression of hybrid plasminogen activators prepared from tissue-type plasminogen activator and urokinase-type plasminogen activator genes.由组织型纤溶酶原激活剂和尿激酶型纤溶酶原激活剂基因制备的杂合纤溶酶原激活剂的构建与表达。
J Biol Chem. 1988 Feb 25;263(6):2917-24.
3
Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.与纤维蛋白结合的1型纤溶酶原激活物抑制剂(PAI-1)与组织型纤溶酶原激活物(t-PA)或尿激酶型纤溶酶原激活物(u-PA)之间的相互作用。t-PA的指状结构域和kringle-2结构域介导t-PA/PAI-1复合物与纤维蛋白的结合。
J Clin Invest. 1989 Aug;84(2):647-55. doi: 10.1172/JCI114211.
4
Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator.吸血蝙蝠唾液纤溶酶原激活剂的分离、特性鉴定及cDNA克隆
J Biol Chem. 1989 Oct 25;264(30):17947-52.
5
Hybrid molecules: insights into plasminogen activator function.杂合分子:对纤溶酶原激活物功能的见解
Mol Biol Med. 1991 Apr;8(2):245-55.
6
Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).组织型纤溶酶原激活剂与尿激酶型纤溶酶原激活剂重组嵌合体(rt-PA/u-PA)的结构域缺失和/或重复突变体的特性分析
Thromb Haemost. 1990 Aug 13;64(1):53-60.
7
Common evolutionary origin of the fibrin-binding structures of fibronectin and tissue-type plasminogen activator.纤连蛋白和组织型纤溶酶原激活物的纤维蛋白结合结构的共同进化起源。
FEBS Lett. 1983 Oct 31;163(1):37-41. doi: 10.1016/0014-5793(83)81157-0.
8
Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.通过结构/功能域的缺失和/或重复获得的人组织型纤溶酶原激活剂变体的生化和功能特性
J Biol Chem. 1990 Apr 5;265(10):5677-83.
9
Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.一种由纤维蛋白片段-D-二聚体特异性人源化单克隆抗体和截短的单链尿激酶组成的重组嵌合纤溶酶原激活剂的特性分析
Eur J Biochem. 1992 Apr 1;205(1):139-46. doi: 10.1111/j.1432-1033.1992.tb16761.x.
10
Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.具有增强纤维蛋白结合能力的重组嵌合纤溶酶原激活剂的特性分析
Biochim Biophys Acta. 2001 Apr 7;1546(2):399-405. doi: 10.1016/s0167-4838(01)00161-3.

引用本文的文献

1
Low-density lipoprotein receptor-related protein-1 (LRP1) in the glial lineage modulates neuronal excitability.神经胶质谱系中的低密度脂蛋白受体相关蛋白1(LRP1)调节神经元兴奋性。
Front Netw Physiol. 2023 Jun 13;3:1190240. doi: 10.3389/fnetp.2023.1190240. eCollection 2023.
2
Roles of the tissue-type plasminogen activator in immune response.组织型纤溶酶原激活物在免疫应答中的作用。
Cell Immunol. 2022 Jan;371:104451. doi: 10.1016/j.cellimm.2021.104451. Epub 2021 Nov 6.
3
The multifaceted role of plasminogen in inflammation.纤溶酶原在炎症中的多效性作用。
Cell Signal. 2020 Nov;75:109761. doi: 10.1016/j.cellsig.2020.109761. Epub 2020 Aug 28.
4
Low Density Receptor-Related Protein 1 Interactions With the Extracellular Matrix: More Than Meets the Eye.低密度受体相关蛋白1与细胞外基质的相互作用:超乎所见。
Front Cell Dev Biol. 2019 Mar 15;7:31. doi: 10.3389/fcell.2019.00031. eCollection 2019.
5
The role of endogenous tissue-type plasminogen activator in neuronal survival after ischemic stroke: friend or foe?内源性组织型纤溶酶原激活物在缺血性脑卒中后神经元存活中的作用:是敌是友?
Cell Mol Life Sci. 2019 Apr;76(8):1489-1506. doi: 10.1007/s00018-019-03005-8. Epub 2019 Jan 17.
6
New strategies in the development of thrombolytic agents.溶栓药物开发的新策略。
Blut. 1988 Oct;57(4):147-62. doi: 10.1007/BF00319543.
7
Autonomous functions of structural domains on human tissue-type plasminogen activator.人组织型纤溶酶原激活剂结构域的自主功能
Proc Natl Acad Sci U S A. 1986 Jul;83(13):4670-4. doi: 10.1073/pnas.83.13.4670.
8
Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin.组织型纤溶酶原激活物的指状结构域和kringle 2结构域参与纤维蛋白结合及纤维蛋白对其活性的刺激作用。
EMBO J. 1986 Dec 20;5(13):3525-30. doi: 10.1002/j.1460-2075.1986.tb04678.x.
9
Variants of human tissue-type plasminogen activator that lack specific structural domains of the heavy chain.缺乏重链特定结构域的人组织型纤溶酶原激活剂变体。
EMBO J. 1988 Sep;7(9):2731-40. doi: 10.1002/j.1460-2075.1988.tb03127.x.
10
Binding of plasminogen activators to fibrin: characterization and pharmacological consequences.纤溶酶原激活剂与纤维蛋白的结合:特性及药理学后果
Biochem J. 1989 Jul 15;261(2):313-24. doi: 10.1042/bj2610313.